Drug Profile
Research programme: T lymphocyte modulators - PanVera
Alternative Names: T lymphocyte modulators research programme - PanVeraLatest Information Update: 21 Oct 2003
Price :
$50
*
At a glance
- Originator PanVera LLC
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunosuppression
Most Recent Events
- 21 Oct 2003 No development reported - Preclinical for Immunosuppression in USA (unspecified route)
- 16 Apr 2003 PanVera LLC has been acquired by Invitrogen
- 21 Aug 2002 Aurora Biosciences Corporation has merged with PanVera Corporation to form PanVera LLC